Company news 2020
sterna biologicals secures EUR 12.0 million (approx. USD 13.0 million) in private placement
Marburg, Germany, May 26, 2020
- Proceeds to fund next Phase 2 clinical study with SB010 in moderate to severe asthma and oral formulation work for SB012 in ulcerative colitis
- Sterna’s approach to down-regulate master transcription factor GATA-3 using a DNAzyme (enzymatic antisense oligonucleotide) enables broad-spectrum, simultaneous intervention in key type 2 inflammatory processes
- Topical treatment with SB010 and SB012 is expected to become a novel, safe and efficacious therapeutic option for chronic inflammatory diseases with high unmet medical need.